Free Access
Med Sci (Paris)
Volume 22, Number 4, Avril 2006
Page(s) 351 - 353
Section Nouvelles
Published online 15 April 2006
  1. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases. Part I : general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104 : 2746–53. [Google Scholar]
  2. Ross R. Atherosclerosis : an inflammatory disease. N Engl J Med 1999; 340 : 115–26. [Google Scholar]
  3. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis : new perspectives and therapeutic strategies. Nat Med 2002; 8 : 1249–56. [Google Scholar]
  4. Froeschl M, Olsen S, Ma X, et al. Current understanding of in-stent restenosis and the potential benefit of drug eluting stents. Curr Drug Targets Cardiovasc Haematol Disord 2004; 4 : 103–17. [Google Scholar]
  5. Hao H, Gabbiani G, Bochaton-Piallat ML. Arterial smooth muscle cell heterogeneity : implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol 2003; 23 : 1510–20. [Google Scholar]
  6. MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors : implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995; 5 : 127–56. [Google Scholar]
  7. Marx N, Duez H, Fruchart JC, et al. Peroxisome proliferator-activated receptors and atherogenesis : regulators of gene expression in vascular cells. Circ Res 2004; 94 : 1168–78. [Google Scholar]
  8. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events : VA-HIT : a randomized controlled trial. JAMA 2001; 285 : 1585–91. [Google Scholar]
  9. Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers : complex stories. Nat Rev Cancer 2004; 4 : 61–70. [Google Scholar]
  10. Gizard F, Amant C, Barbier O, et al. PPARalpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16. J Clin Invest 2005; 115 : 3228–38. [Google Scholar]
  11. Carmeliet P, Moons L, Herbert JM, et al. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997; 81 : 829–39. [Google Scholar]
  12. Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 1999; 9 : 22–30. [Google Scholar]
  13. Krimpenfort P, Quon KC, Mooi WJ, et al. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001; 413 : 83–6. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.